INT163458

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.61
Pain Relevance 0.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

pigmentation (Kit) cell differentiation (Kit) extracellular space (Kit)
plasma membrane (Kit) nucleus (Kit) kinase activity (Kit)
Anatomy Link Frequency
platelet 2
Kit (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 1 60.16 Quite High
antagonist 1 17.84 Low Low
imagery 24 5.00 Very Low Very Low Very Low
positron emission tomography 7 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
Bioavailability 1 5.00 Very Low Very Low Very Low
metalloproteinase 1 5.00 Very Low Very Low Very Low
chemokine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 4 98.00 Very High Very High Very High
Gastrointestinal Stromal Tumor 7 95.28 Very High Very High Very High
Myeloid Leukemia 4 93.16 High High
Leukemia 2 92.96 High High
Hematologic Neoplasms 1 78.84 Quite High
Cancer 92 72.88 Quite High
Tumor Necrosis Factor Receptor-associated Periodic Syndrome 1 62.48 Quite High
Arthralgia 1 60.64 Quite High
Cramps 1 59.68 Quite High
Pressure And Volume Under Development 1 58.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The introduction of imatinib, a tyrosine kinase inhibitor mainly targeting BCR-ABL, c-KIT and PDGFR, has profoundly improved the prognosis of both entities, while being surprisingly well tolerated.
Negative_regulation (inhibitor) of Regulation (targeting) of c-KIT
1) Confidence 0.12 Published 2009 Journal Drug Saf Section Abstract Doc Link 19810774 Disease Relevance 1.17 Pain Relevance 0.06
Sunitinib and sorafenib are multitargeting TKIs that can block activity angiogenic targets such as of VEGFR1, 2, 3, platelet-derived growth factor (PDGF) receptors and c-Kit or RET.
Negative_regulation (block) of Regulation (targets) of c-Kit in platelet
2) Confidence 0.05 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.44 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox